Patient-researchers tackle Ehlers-Danlos syndromes; Covid test maker pivots to being an insurer

A generation of young patient-researchers are advancing the science of Ehlers-Danlos syndrome, which they had to fight to get recognized. ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

Sponsored by      Revenge of the gaslit patients: Now, as scientists, they're tackling Ehlers-Danlos syndromes By Isabella Cueto Maria Fabrizio for STAT A generation of young patient-researchers are advancing the science of Ehlers-Danlos syndrome, which they had to fight to get recognized. Read More STAT+: The Covid-19 test maker that pivoted to being a health insurance company By Bob Herman Courtesy Curative Curative's Covid-19 test business is now firmly in the past. The company has switched to an even more regulated industry: health insurance. Read More STAT+: Amgen's $27.8 billion Horizon merger is latest industry bet on pricey rare disease drugs By Matthew Herper and Jason Mast Ruby Wallau for STAT The largest pharma merger this year illustrates how expensive rare-disease drugs have become among the industry's most profitable bets. Read More Sponsored Insight by GENENTECH, A MEMBER OF THE ROCHE GROUP Pursuing a better future for people living with hematologic disorders Hematologic disorders, including non-Hodgkin's lymphomas and others, significantly impact the lives of millions of Americans. Innovative immunotherapies and other novel medicines have the potential to offer hope to these individuals for a longer life and reduce burdens at various stages of their treatment journey. Scientists at Genentech are pursuing therapeutic innovations to improve outcomes for people with hematologic disorders and rethinking what is possible when it comes to standards of care and the patient experience. Learn more about how research has made important strides in treating various types of blood diseases. STAT+: Coming soon: Permanent Covid-19 safety rules for health care workers By Tara Bannow David Ryder/Getty Images OSHA’s moving forward with permanent Covid-19 safety rules for health care workers. Nurse unions are thrilled. Hospitals, not so much. Read More STAT+: Affimed's natural killer cell therapy has murky path forward despite encouraging results By Adam Feuerstein NIAID/NIH An experimental immunotherapy from Affimed has started to demonstrate long-lasting remissions for patients with advanced Hodgkin lymphoma. Read More STAT+: Roche pharmaceuticals CEO Bill Anderson to step down after four-year tenure By Jason Mast SEBASTIEN BOZON/AFP via Getty Images In the last year, Roche watched two of its most closely watched drug candidates fail to yield results in late-stage trials. Read More STAT+: Cambodia halts exports of non-human primates, threatening drug discovery efforts By Ed Silverman Courtesy Tulane National Primate Research Center "Depending on the duration of restrictions on imports. drug discovery and development in the US could be materially impacted" Inotiv said. Read More Opinion: Responsibly expanding access to methadone for people with opioid use disorder will save lives By Greg Rudolf David Goldman/AP Unscientific regulations that limit access to methadone prevent many people with opioid use disorder from receiving this lifesaving medicine. Read More Monday, December 12, 2022       1 Exchange Pl, Suite 201, Boston, MA 02109 ©2022, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us | View In Browser